高管介绍
暂无数据
董事简历
中英对照 | 中文 | 英文- Kristina Burow
-
Kristina Burow，2010年2月起，她担任我公司董事，也是我公司创始人之一。2002年，她加入ARCH Venture Partners，担任总经理。她是Sapphire Energy的共同创始人和董事以及Lycera Corp., Limerick BioPharma, Inc., AgBiome, LLC, BlackThorn Therapeutics, Cenexys, Inc.和Kilimanjaro Energy的董事。 加入ARCH之前，她曾担任圣地亚哥Novartis BioVenture Fund的副会长参与许多生命科学的投资。作为Genomics Institute of the Novartis Research Foundation GNF的早期职员，她领导了化学运营，活跃于商业发展，帮助成立了许多GNF的衍生公司。她在芝加哥大学（University of Chicago）获得工商管理学硕士学位， 在哥伦比亚大学（Columbia University）获得化学硕士学位并在加利福尼亚大学伯克利分校（University of California, Berkeley）获得化学学士学位。
Kristina Burow has served on our board of directors since January 2018. She has served as a Managing Director with ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow also currently serves on the boards of directors of Vividion Therapeutics, Inc., Beam Therapeutics Inc., Metacrine, Inc., Scholar Rock, Inc., Unity Biotechnology Inc., AgBiome Inc., Boundless Bio, Inc., Autobahn Therapeutics, Inc., Rome Therapeutics and Boragen Inc. and was previously a director at VIR Biotechnology, Inc. Ms. Burow previously was a co-founder and director of Receptos, Inc. prior to its acquisition. Prior to ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a B.A. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago. - Kristina Burow，2010年2月起，她担任我公司董事，也是我公司创始人之一。2002年，她加入ARCH Venture Partners，担任总经理。她是Sapphire Energy的共同创始人和董事以及Lycera Corp., Limerick BioPharma, Inc., AgBiome, LLC, BlackThorn Therapeutics, Cenexys, Inc.和Kilimanjaro Energy的董事。 加入ARCH之前，她曾担任圣地亚哥Novartis BioVenture Fund的副会长参与许多生命科学的投资。作为Genomics Institute of the Novartis Research Foundation GNF的早期职员，她领导了化学运营，活跃于商业发展，帮助成立了许多GNF的衍生公司。她在芝加哥大学（University of Chicago）获得工商管理学硕士学位， 在哥伦比亚大学（Columbia University）获得化学硕士学位并在加利福尼亚大学伯克利分校（University of California, Berkeley）获得化学学士学位。
- Kristina Burow has served on our board of directors since January 2018. She has served as a Managing Director with ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow also currently serves on the boards of directors of Vividion Therapeutics, Inc., Beam Therapeutics Inc., Metacrine, Inc., Scholar Rock, Inc., Unity Biotechnology Inc., AgBiome Inc., Boundless Bio, Inc., Autobahn Therapeutics, Inc., Rome Therapeutics and Boragen Inc. and was previously a director at VIR Biotechnology, Inc. Ms. Burow previously was a co-founder and director of Receptos, Inc. prior to its acquisition. Prior to ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a B.A. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago.